<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01985542</url>
  </required_header>
  <id_info>
    <org_study_id>The effects of immunotherapy</org_study_id>
    <nct_id>NCT01985542</nct_id>
  </id_info>
  <brief_title>The Effects of Immunotherapy in the Nose</brief_title>
  <acronym>Birch11</acronym>
  <official_title>The Molecular Biological Effects of Immunotherapy in the Nose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Helsinki</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Finnish Institute of Occupational Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allergic rhinitis might be caused by decreased resistance of nasal barrier to allergens and&#xD;
      other environmental insults. About 20 % of the European population suffers from pollen&#xD;
      allergies. Birch pollen allergic rhinitis is the most common allergic disease in the&#xD;
      Scandinavia and it exists widely also in the Central Europe. Suffering and high costs of&#xD;
      pollen allergies may be reduced by understanding the molecular biology of the nasal barriers&#xD;
      during allergic response. Our aim is to observe the effect of season and birch pollen&#xD;
      immunotherapy on the molecular biology of nasal epithelium and the microbiome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a controlled study with an intervention arm, and a control group of healthy&#xD;
      volunteers. The population is composed of nonsmoking healthy adults and patients having birch&#xD;
      or timothy pollen allergy with rhinoconjuctivitis symptoms and without other diseases. The&#xD;
      diagnosis of pollen allergy is verified with positive history, skin prick test, and allergen&#xD;
      specific IgE antibodies. Subjects undergo a spirometry with a bronchodilatator test and a&#xD;
      histamine challenge. Quality of life and patient history data is collected by questionnaires.&#xD;
      Four peripheral blood samples, as well as nasal cell swabs from nasal mucosa without local&#xD;
      anesthesia are collected from each patient; in spring and winter before the group of the&#xD;
      intervention arm starts with birch pollen subcutaneous immunotherapy; and during the first&#xD;
      spring and winter when a subgroups has received the birch pollen immunotherapy. We plan to&#xD;
      perform the following analyses for the nasal specimens: transcriptomics and their regulators,&#xD;
      sequencing of 16SrRNA and RT-qPCR for assessing mucosal microbiome, mass spectrometry for&#xD;
      analyses of proteins and protein-protein complexes, immunohistochemistry for tissue level&#xD;
      localization and quantitation of proteins, in silico analyses for the data mining,&#xD;
      integration and display. In addition we observe the alterations in inflammatory mediators&#xD;
      after in vitro allergen activation of purified peripheral blood leukocytes by ELISA and real&#xD;
      time qPCR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Total Number of Differentially Expressed Transcripts.</measure>
    <time_frame>-6 months vs. +6 months from the starting point of birch pollen subcutaneous immunotherapy.</time_frame>
    <description>Transcriptomics are evaluated By Next Generation Sequencing. The total number of differentially expressed transcripts are defined from nasal epithelial brushing samples taken at -6 months vs. at +6 months in the two subject groups.&#xD;
The subject groups are the Subcutaneous immunotherapy group and No immunotherapy group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Visual Analogue Scale Scores of Symptoms</measure>
    <time_frame>-6 months vs. +6 months from the starting point of birch pollen subcutaneous immunotherapy.</time_frame>
    <description>Visual analogue scale (VAS) was measured as 0-100 mm per each symptom question. VAS value 0 (mm) indicates no symptoms, and value 100 (mm) indicates the worst case.&#xD;
Total VAS score = sum of the VAS scores for the 41 symptoms The minimum value of the total VAS score is 0, and the maximum value is 4100. Relative change = [(measure at time +6 months - measure at time -6 months)]/measure at time -6 months * 100%.&#xD;
Measure = total VAS score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Rhinitis, Allergic, Seasonal</condition>
  <arm_group>
    <arm_group_label>subcutaneous immunotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Starts with birch pollen subcutaneous immunotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no immunotherapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>not starting with birch pollen subcutaneous immunotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>birch pollen subcutaneous immunotherapy</intervention_name>
    <description>birch pollen subcutaneous immunotherapy</description>
    <arm_group_label>subcutaneous immunotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  allergic rhinoconjunctivitis of birch pollen OR healthy controls&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  smoking, asthma, any other disease than allergic rhinoconjunctivitis, requiring&#xD;
             constant medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sanna K Salmi, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <reference>
    <citation>Mattila P, Renkonen J, Toppila-Salmi S, Parviainen V, Joenväärä S, Alff-Tuomala S, Nicorici D, Renkonen R. Time-series nasal epithelial transcriptomics during natural pollen exposure in healthy subjects and allergic patients. Allergy. 2010 Feb;65(2):175-83. doi: 10.1111/j.1398-9995.2009.02181.x. Epub 2009 Oct 5.</citation>
    <PMID>19804444</PMID>
  </reference>
  <reference>
    <citation>Joenväärä S, Mattila P, Renkonen J, Mäkitie A, Toppila-Salmi S, Lehtonen M, Salmi P, Lehti S, Mäkinen J, Sormunen R, Paavonen T, Renkonen R. Caveolar transport through nasal epithelium of birch pollen allergen Bet v 1 in allergic patients. J Allergy Clin Immunol. 2009 Jul;124(1):135-142.e1-21. doi: 10.1016/j.jaci.2008.11.048. Epub 2009 Apr 2.</citation>
    <PMID>19344938</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 4, 2013</study_first_submitted>
  <study_first_submitted_qc>November 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2013</study_first_posted>
  <results_first_submitted>March 9, 2019</results_first_submitted>
  <results_first_submitted_qc>March 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 20, 2021</results_first_posted>
  <last_update_submitted>May 30, 2021</last_update_submitted>
  <last_update_submitted_qc>May 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Sanna Salmi</investigator_full_name>
    <investigator_title>MD PhD, Docent</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The individual participant data is not shared.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Subcutaneous Immunotherapy</title>
          <description>Starts with birch pollen subcutaneous immunotherapy&#xD;
birch pollen subcutaneous immunotherapy: birch pollen subcutaneous immunotherapy</description>
        </group>
        <group group_id="P2">
          <title>no Immunotherapy</title>
          <description>not starting with birch pollen subcutaneous immunotherapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Immunotherapy group is starting with subcutaneuous birch pollen immunotherapy (AIT) with normal protocol of the Hospital. Control group is not starting AIT.</population>
      <group_list>
        <group group_id="B1">
          <title>Subcutaneous Immunotherapy</title>
          <description>Starting with subcutaneuous birch pollen immunotherapy with normal protocol of the Hospital</description>
        </group>
        <group group_id="B2">
          <title>no Immunotherapy</title>
          <description>Birch pollen allergic subjects that are not starting with immunotherapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Volunteers</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40" lower_limit="37" upper_limit="45"/>
                    <measurement group_id="B2" value="34" lower_limit="30" upper_limit="49"/>
                    <measurement group_id="B3" value="38.5" lower_limit="30" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Total Number of Differentially Expressed Transcripts.</title>
        <description>Transcriptomics are evaluated By Next Generation Sequencing. The total number of differentially expressed transcripts are defined from nasal epithelial brushing samples taken at -6 months vs. at +6 months in the two subject groups.&#xD;
The subject groups are the Subcutaneous immunotherapy group and No immunotherapy group.</description>
        <time_frame>-6 months vs. +6 months from the starting point of birch pollen subcutaneous immunotherapy.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous Immunotherapy</title>
            <description>Subjects with birch pollen allergic rhinitis.</description>
          </group>
          <group group_id="O2">
            <title>No Immunotherapy</title>
            <description>Subjects with birch pollen allergic rhinitis.</description>
          </group>
        </group_list>
        <measure>
          <title>The Total Number of Differentially Expressed Transcripts.</title>
          <description>Transcriptomics are evaluated By Next Generation Sequencing. The total number of differentially expressed transcripts are defined from nasal epithelial brushing samples taken at -6 months vs. at +6 months in the two subject groups.&#xD;
The subject groups are the Subcutaneous immunotherapy group and No immunotherapy group.</description>
          <units>transcripts</units>
          <param>Number</param>
          <units_analyzed>nasal brushing sample</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>nasal brushing sample</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Visual Analogue Scale Scores of Symptoms</title>
        <description>Visual analogue scale (VAS) was measured as 0-100 mm per each symptom question. VAS value 0 (mm) indicates no symptoms, and value 100 (mm) indicates the worst case.&#xD;
Total VAS score = sum of the VAS scores for the 41 symptoms The minimum value of the total VAS score is 0, and the maximum value is 4100. Relative change = [(measure at time +6 months - measure at time -6 months)]/measure at time -6 months * 100%.&#xD;
Measure = total VAS score</description>
        <time_frame>-6 months vs. +6 months from the starting point of birch pollen subcutaneous immunotherapy.</time_frame>
        <population>The subject groups are the Subcutaneous immunotherapy group and No immunotherapy group.</population>
        <group_list>
          <group group_id="O1">
            <title>Immunotherapy</title>
            <description>Subjects with birch pollen allergic rhinitis.</description>
          </group>
          <group group_id="O2">
            <title>No Immunotherapy</title>
            <description>Subjects with birch pollen allergic rhinitis.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Visual Analogue Scale Scores of Symptoms</title>
          <description>Visual analogue scale (VAS) was measured as 0-100 mm per each symptom question. VAS value 0 (mm) indicates no symptoms, and value 100 (mm) indicates the worst case.&#xD;
Total VAS score = sum of the VAS scores for the 41 symptoms The minimum value of the total VAS score is 0, and the maximum value is 4100. Relative change = [(measure at time +6 months - measure at time -6 months)]/measure at time -6 months * 100%.&#xD;
Measure = total VAS score</description>
          <population>The subject groups are the Subcutaneous immunotherapy group and No immunotherapy group.</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-68" lower_limit="-76" upper_limit="-7"/>
                    <measurement group_id="O2" value="91" lower_limit="-49" upper_limit="347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study completion, an average of 18 months</time_frame>
      <desc>Interview and marking to Immunotherapy form of the patient records.</desc>
      <group_list>
        <group group_id="E1">
          <title>Subcutaneous Immunotherapy</title>
          <description>Starts with birch pollen subcutaneous immunotherapy&#xD;
birch pollen subcutaneous immunotherapy: birch pollen subcutaneous immunotherapy</description>
        </group>
        <group group_id="E2">
          <title>no Immunotherapy</title>
          <description>not starting with birch pollen subcutaneous immunotherapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sanna Salmi</name_or_title>
      <organization>Helsinki University Hospital</organization>
      <phone>+358505431421</phone>
      <email>sanna.salmi@helsinki.fi</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

